The Role of Cardiac Fibrosis and Fibroblast Activation in Amyloid Light Chain (AL) Amyloidosis
Open Access
- 27 August 2026
- journal article
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (9) , 101653
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 43 references indexed in Scilit:
- Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic PrecisionJACC: Cardiovascular Imaging, 2025
- Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatmentAmerican Journal of Hematology, 2023
- A web-based integrative transcriptome analysis, RNAseqChef, uncovers the cell/tissue type-dependent action of sulforaphaneJournal of Biological Chemistry, 2023
- AL Amyloidosis for CardiologistsJACC: Cardiooncology, 2022
- Fibroblast ActivationJACC: Cardiovascular Imaging, 2022
- Utility of Biomarkers in Cardiac AmyloidosisJACC: Heart Failure, 2020
- Cardiac Fibrosis Is Associated With Decreased Circulating Levels of Full-Length CILP in Heart FailureJACC: Basic To Translational Science, 2020
- Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015JAMA Cardiology, 2018
- Myocardial Interstitial Fibrosis in Heart FailureJACC, 2018
- AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cellsLaboratory Investigation, 2004